Design Therapeutics (DSGN) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Verastem (VSTM) over the past year, gaining 80.1% versus a loss of 8.2%. Over five years, DSGN leads with a -18.0% price change compared with -75.0% for VSTM. Verastem is the larger company by market cap ($748.5 million vs $731.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DSGN | VSTM |
|---|---|---|
| Share price | $11.69 | $8.27 |
| Market cap | $731.58M | $748.51M |
| 1-day change | -2.34% | +6.65% |
| YTD return | +24.63% | +7.06% |
| 1-year return | +80.12% | -8.17% |
| 5-year return | -17.96% | -75.05% |
| EPS (TTM) | $-1.18 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $10.82 |
| 52-week low | $5.28 | $3.43 |
| Distance from 52-week high | -32.23% | -23.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +85.71% | +77.50% |
| Average volume | 607.69K | 2.26M |
| Shares outstanding | 62.58M | 90.56M |
| Employees | 55 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed VSTM by 88.3 percentage points over the past year.
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
DSGN vs VSTM FAQ
Which is bigger, Design Therapeutics or Verastem?
Verastem (VSTM) is larger, with a market capitalization of $748.51M compared with $731.58M for Design Therapeutics (DSGN).
Which stock has performed better over the past year, DSGN or VSTM?
DSGN returned +80.12% over the past 12 months, compared with -8.17% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Design Therapeutics and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.